Relmada Therapeutics Inc. has approved amended and restated employment agreements for its executive officers, effective January 1, 2026. Under the new terms, Chief Executive Officer Sergio Traversa's annual salary will increase from $787,787 to $827,176. Chief Operating Officer Paul Kelly's salary will rise from $499,800 to $524,790, and he will be eligible for twelve months' severance and health benefits if terminated without cause or resigning for good reason. In the event of a termination or resignation for good reason within 12 months following a change in control, Kelly's severance increases to 18 months of compensation, with continued health benefits for twelve months. Chief Financial Officer Maged Shenouda's salary will increase from $558,990 to $586,940, with health benefits continuing for at least twelve months or until eligible for Medicare if separated. Chief Accounting and Compliance Officer Charles Ence's salary will rise from $548,990 to $576,440.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-121461), on December 15, 2025, and is solely responsible for the information contained therein.
Comments